de Boer Mark G J, Gieling Emilie M, van der Linden Paul D, Sinha Bhanu N M, Vollaard Albert M
LUMC, afd. Infectieziekten, Leiden.
Contact: Mark G.J. de Boer (
Ned Tijdschr Geneeskd. 2020 Nov 12;164:D5620.
Much has changed in the medical treatment of COVID-19 after the first patient with an infection with SARS-CoV-2 in the Netherlands was diagnosed in February 2020. On the basis of limited data, at first only off-label use of (hydroxy)chloroquine seemed to be a treatment option. However, now based on the findings of several randomized studies, other medicines have been included in the Dutch guidelines about the treatment of COVID-19. In this article, we will briefly discuss the current state of affairs with regard to the drugs (hydroxy) chloroquine, remdesivir and corticosteroids. Again, it appears that only well-executed randomized clinical trials can determine the status of various supposedly effective drugs.
自2020年2月荷兰首例感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的患者被确诊以来,新型冠状病毒肺炎(COVID-19)的医学治疗发生了很大变化。基于有限的数据,起初只有(羟)氯喹的超说明书用药似乎是一种治疗选择。然而,现在根据多项随机研究的结果,其他药物已被纳入荷兰关于COVID-19治疗的指南中。在本文中,我们将简要讨论(羟)氯喹、瑞德西韦和皮质类固醇药物的当前情况。同样,似乎只有精心实施的随机临床试验才能确定各种所谓有效药物的地位。